Coming Soon: Bio-Reference Laboratories Earnings
Bio-Reference Laboratories (NAS: BRLI) is expected to report Q2 earnings around May 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Bio-Reference Laboratories's revenues will expand 7.8% and EPS will expand 24.2%.
The average estimate for revenue is $176.1 million. On the bottom line, the average EPS estimate is $0.41.
Last quarter, Bio-Reference Laboratories reported revenue of $161.3 million. GAAP reported sales were 16% higher than the prior-year quarter's $138.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.31. GAAP EPS of $0.31 for Q1 were 19% higher than the prior-year quarter's $0.26 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 46.2%, 70 basis points better than the prior-year quarter. Operating margin was 9.8%, 20 basis points better than the prior-year quarter. Net margin was 5.4%, 10 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $711.3 million. The average EPS estimate is $1.78.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 313 members out of 334 rating the stock outperform, and 21 members rating it underperform. Among 103 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 97 give Bio-Reference Laboratories a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Reference Laboratories is outperform, with an average price target of $31.00.
Is Bio-Reference Laboratories the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Bio-Reference Laboratories to My Watchlist.
The article Coming Soon: Bio-Reference Laboratories Earnings originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Bio-Reference Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.